Mediator kinase inhibition drives myometrial stem cell differentiation and the uterine fibroid phenotype through super-enhancer reprogramming
- PMID: 39904883
- PMCID: PMC11880082
- DOI: 10.1007/s00109-025-02517-0
Mediator kinase inhibition drives myometrial stem cell differentiation and the uterine fibroid phenotype through super-enhancer reprogramming
Abstract
Uterine fibroids (UFs) are the most common non-cutaneous tumors in women worldwide. UFs arise from genetic alterations in myometrial stem cells (MM SCs) that trigger their transformation into tumor-initiating cells (UF SCs). Mutations in the RNA polymerase II Mediator subunit MED12 are dominant drivers of UFs, accounting for 70% of these clinically significant lesions. Biochemically, UF driver mutations in MED12 disrupt CDK8/19 kinase activity in Mediator, but how Mediator kinase disruption triggers MM SC transformation remains unknown. Here, we show that pharmacologic inhibition of CDK8/19 in MM SCs removes a barrier to myogenic differentiation down an altered pathway characterized by molecular phenotypes characteristic of UFs, including oncogenic growth and extracellular matrix (ECM) production. These perturbations appear to be induced by transcriptomic changes, arising in part through epigenomic alteration and super-enhancer reprogramming, that broadly recapitulate those found in MED12-mutant UFs. Altogether, these findings provide new insights concerning the biological role of CDK8/19 in MM SC biology and UF formation. KEY MESSAGES: Mediator kinase inhibition in myometrial stem cells (MM SCs) induces spontaneous differentiation. Transcriptional changes upon Mediator kinase inhibition recapitulate those of MED12 mutant uterine fibroids (UFs). Such transcriptional changes are partially mediated by super-enhancer reprogramming. Mediator kinase functions to enforce cell states and its loss induces cellular plasticity.
Keywords: Cell plasticity; Differentiation; Mediator kinase; Stem cells; Super-enhancer; Uterine fibroids.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. The UT Health San Antonio Institutional Review Board approved the protocol for recovery of surgical specimens. Consent to participate: Informed consent was obtained from all individual participants included in the study. Competing interests: The authors declare no competing interests.
Figures
Update of
-
Mediator kinase inhibition drives myometrial stem cell differentiation and the uterine fibroid phenotype through super-enhancer reprogramming.Res Sq [Preprint]. 2024 Dec 16:rs.3.rs-5125876. doi: 10.21203/rs.3.rs-5125876/v1. Res Sq. 2024. Update in: J Mol Med (Berl). 2025 Mar;103(3):311-326. doi: 10.1007/s00109-025-02517-0. PMID: 39764110 Free PMC article. Updated. Preprint.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
